Fosun Pharma gets approval for $564m share sale
Shanghai Fosun Pharmaceutical Group has been given the go-ahead to raise as much as HK$4.4bn ($564m) in new equity, amid reports the company is bidding for Novartis’s assets.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: